Agilent Technologies, Inc. (NYSE:A) Stock Has Consensus Price Target of $173.65

Shares of Agilent Technologies, Inc. (NYSE:A - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nineteen research firms that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $173.65.

A number of equities research analysts recently issued reports on the stock. Barclays upped their price objective on shares of Agilent Technologies from $175.00 to $195.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. UBS Group began coverage on Agilent Technologies in a report on Wednesday, September 9th. They set a "neutral" rating and a $165.00 target price on the stock. Stifel Nicolaus raised their target price on Agilent Technologies from $170.00 to $180.00 and gave the company a "buy" rating in a report on Thursday, August 27th. Bank of America boosted their price target on Agilent Technologies from $155.00 to $180.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Finally, Royal Bank Of Canada boosted their price target on Agilent Technologies from $155.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, August 27th.

Agilent Technologies Price Performance

NYSE A opened at $173.09 on Wednesday. The company has a quick ratio of 1.56, a current ratio of 2.05 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $48.80 billion, a PE ratio of 34.07, a price-to-earnings-growth ratio of 2.59 and a beta of 1.21. Agilent Technologies has a 12-month low of $108.35 and a 12-month high of $177.47. The company has a 50 day moving average price of $159.90 and a two-hundred day moving average price of $138.53.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.49 by $0.13. The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. Agilent Technologies's quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, equities analysts predict that Agilent Technologies will post 6.20 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 28th. Stockholders of record on Tuesday, October 6th will be issued a dividend of $0.2550 per share. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.6%. Agilent Technologies's dividend payout ratio is currently 20.08%.

Insider Buying and Selling at Agilent Technologies

In related news, Director Mikael Dolsten sold 634 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $151.38, for a total value of $95,974.92. Following the transaction, the director directly owned 4,924 shares of the company's stock, valued at approximately $745,395.12. This trade represents a 11.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Institutional Investors Weigh In On Agilent Technologies

Large investors have recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in shares of Agilent Technologies by 0.7% during the second quarter. State Street Corp now owns 12,854,230 shares of the medical research company's stock worth $1,710,658,000 after buying an additional 89,598 shares during the last quarter. Wellington Management Group LLP raised its stake in Agilent Technologies by 2.7% during the 2nd quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company's stock valued at $990,206,000 after purchasing an additional 198,253 shares during the last quarter. Deutsche Bank AG raised its stake in Agilent Technologies by 17.1% during the 2nd quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company's stock valued at $930,957,000 after purchasing an additional 1,024,516 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Agilent Technologies by 87.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company's stock valued at $695,227,000 after purchasing an additional 2,440,360 shares during the period. Finally, Legal & General Group Plc bought a new stake in Agilent Technologies in the 2nd quarter valued at $260,101,000.

Agilent Technologies Company Profile

Agilent Technologies, Inc is a global provider of analytical laboratory instruments, software, services and consumables. The company serves customers in the pharmaceutical, biotechnology, chemical, food, environmental, energy and academic research sectors, as well as diagnostic and clinical laboratories.

Agilent's offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic instruments, laboratory automation products, genomic and cell analysis solutions, and related software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.